| ■ 영문 제목 : Rare Disease Clinical Trials Market Size, Share & Trends Analysis Report By Therapeutic Area (Autoimmune & Inflammation, Hematologic Disorders), By Phase (Phase I, Phase II), By Sponsor, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MR025
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 2월
■ 페이지수 : 225
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 희소 질환 임상 시험 시장 규모가 2023년부터 2030년 사이에 CAGR 9.7% 증가하여, 2030년에는 242.5억 달러에 달할 것으로 전망하고 있습니다. 본 자료는 세계의 희소 질환 임상 시험 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 치료 영역별 (종양, 심혈관계 질환, 신경계 질환, 감염증, 기타) 분석, 단계별 (단계Ⅰ, 단계Ⅱ, 단계Ⅲ, 단계Ⅳ) 분석, 스폰서별 (제약 및 바이오 의약품 기업, 비영리 단체, 기타) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카) 분석, 경쟁 현황, 기업 정보 등의 항목을 수록하고 있습니다. 덧붙여 본 리포트는 Takeda Pharmaceutical Company, F. Hoffmann -La Roche Ltd., Pfizer, Inc., AstraZeneca, Novartis AG, Labcorp Drug Development, IQVIA, Inc., Charles River Laboratories, Icon Plc, Parexel International Corporation 등의 기업 정보가 포함되어 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 희소 질환 임상 시험 시장 규모 : 치료 영역별
- 종양 치료에 사용되는 희소 질환 임상 시험의 시장 규모
- 심혈관계 질환 치료에 사용되는 희소 질환 임상 시험의 시장 규모
- 신경계 질환 치료에 사용되는 희소 질환 임상 시험의 시장 규모
- 감염 치료에 사용되는 희소 질환 임상 시험의 시장 규모
- 기타 치료에 사용되는 희소 질환 임상 시험의 시장 규모
・세계의 희소 질환 임상 시험 시장 규모 : 단계별
- 단계Ⅰ희소 질환 임상 시험의 시장 규모
- 단계Ⅱ 희소 질환 임상 시험의 시장 규모
- 단계Ⅲ 희소 질환 임상 시험의 시장 규모
- 단계Ⅳ 희소 질환 임상 시험의 시장 규모
・세계의 희소 질환 임상 시험 규모 : 스폰서별
- 제약 및 바이오 의약품 기업 스폰서의 시장 규모
- 비영리 단체 스폰서의 시장 규모
- 기타 스폰서의 시장 규모
・세계의 희소 질환 임상 시험 시장 규모 : 지역별
- 북미의 희소 질환 임상 시험 시장 규모
- 유럽의 희소 질환 임상 시험 시장 규모
- 아시아 태평양의 희소 질환 임상 시험 시장 규모
- 중남미의 희소 질환 임상 시험 시장 규모
- 중동 및 아프리카의 희소 질환 임상 시험 시장 규모
・경쟁 현황
・기업 정보 |
■ 보고서 개요Rare Disease Clinical Trials Market Growth & Trends
The global rare disease clinical trials market size is expected to reach USD 24.25 billion by 2030, expanding at 9.7% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The main driving factors of the rare disease clinical trial industry are the high burden of rare diseases worldwide, which has led to rising demand for research. Furthermore, intermittent launches and a large number of products in the pipeline also propel growth. Government initiatives that encourage product development, such as the Orphan Drug Act, are further expected to assist industry growth.
According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases worldwide. These diseases affect nearly 30 million Americans, or 1 in every 10 people. Eurodis states that 72% of rare diseases are genetic, while others are caused by infections, allergies, and environmental causes. The growing awareness among people regarding rare diseases and growing interest in developing potential treatments for treating rare diseases are expected to support market growth.
Pharmaceutical companies and non-profit organizations are actively providing funding for rare disease clinical research. For instance, in February 2022, the Health Research Board funded USD 1.1 million to support rare disease clinical trials. Similar initiatives in the future are expected to support the market during the forecast period.
Orphan drug sales have been steadily increasing in recent years. For instance, according to Evaluate Pharma, orphan drug sales accounted for USD 138 billion in 2020, and by 2022, they accounted for USD 172 billion. It is estimated that orphan drug sales will reach USD 268 billion by 2026. The rise in the sales of orphan drugs is expected to generate interest among researchers in developing new treatments in the area of rare diseases and thus support the market in the post-pandemic period.
Rare Disease Clinical Trials Market Report Highlights
• The phase III segment is expected to grow at the fastest CAGR of 10.3% during the forecast period. The segment’s growth is supported by the high cost of phase III rare disease clinical trials due to the requirement for a large number of volunteers
• The oncology segment held the largest market revenue share of 33.9% in 2022. The growing interest of researchers in the development of new potential treatments for treating rare cancers is supporting the growth of the segment
• Based on the sponsor, the nonprofit organization segment is expected to grow at a CAGR of 9.9% over the forecast period owing to the significant funding offered by these organizations to support rare disease clinical research
• North America dominated the market and accounted for a revenue share of 49.3% in 2022. The high burden of rare diseases in North America and the presence of a large number of players in clinical trials are some of the key reasons for its high market share
■ 보고서 목차Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapeutic Area
1.1.2. Phase
1.1.3. Sponsors
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Rare Disease Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Significant number of clinical research fundings for rare diseases clinical trials
3.2.1.2. Growing interest of researchers in the area of rare disease clinical trials
3.2.1.3. Increase in the number of collaborations by pharmaceutical companies to conduct rare disease clinical trials.
3.2.2. Market restraint analysis
3.2.2.1. High cost of rare diseases clinical trials and high attrition rate
3.3. Rare Disease Clinical Trials: Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis and Reformation Strategies
Chapter 4. Rare Disease Clinical Trials Market: Therapeutic Area Estimates & Trend Analysis
4.1. Rare Disease Clinical Trials Market: Definitions and Scope
4.2. Rare Disease Clinical Trials Market: Therapeutic Area Market Share Analysis, 2022 & 2030
4.2.1. Oncology
4.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Million)
4.2.2. Cardiovascular Disorders
4.2.2.1. Cardiovascular Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.3. Neurological Disorders
4.2.3.1. Neurological Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.4. Infectious Disease
4.2.4.1. Infectious Disease Market estimates and forecast 2018 to 2030 (USD Million)
4.2.5. Genetic Disorders
4.2.5.1. Metabolic Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.6. Autoimmune and Inflammation
4.2.6.1. Autoimmune and Inflammation Market estimates and forecast 2018 to 2030 (USD Million)
4.2.7. Hematologic Disorders
4.2.7.1. Hematologic Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.8. Musculoskeletal Disorders
4.2.8.1. Musculoskeletal Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.9. Others
4.2.9.1. Others Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Rare Disease Clinical Trials Market: Phase Estimates & Trend Analysis
5.1. Rare Disease Clinical Trials Market: Definitions and Scope
5.2. Rare Disease Clinical Trials Market: Phase Market Share Analysis, 2022 & 2030
5.2.1. Phase I
5.2.1.1. Phase I Market estimates and forecast 2018 to 2030 (USD Million)
5.2.2. Phase II
5.2.2.1. Phase II Market estimates and forecast 2018 to 2030 (USD Million)
5.2.3. Phase III
5.2.3.1. Phase III Market estimates and forecast 2018 to 2030 (USD Million)
5.2.4. Phase IV
5.2.4.1. Phase IV Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Rare Disease Clinical Trials Market: Sponsor Estimates & Trend Analysis
6.1. Rare Disease Clinical Trials Market: Definitions and Scope
6.2. Rare Disease Clinical Trials Market: Sponsor Market Share Analysis, 2022 & 2030
6.2.1. Pharmaceutical & Biopharmaceutical Companies
6.2.1.1. Pharmaceutical & Biopharmaceutical Companies Market estimates and forecast 2018 to 2030 (USD Million)
6.2.2. Non-Profit Organizations
6.2.2.1. Non-Profit Organizations Market estimates and forecast 2018 to 2030 (USD Million)
6.2.3. Others
6.2.3.1. Others Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Rare Disease Clinical Trials Market: Regional Estimates & Trend Analysis
7.1. Regional market share analysis, 2022 & 2030
7.2. Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. Market estimates and forecast, 2018 – 2030 (Value)
7.3.2. U.S.
7.3.2.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4. Europe
7.4.1. U.K.
7.4.1.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.6. Denmark
7.4.6.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.4.8. Norway
7.4.8.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecast, 2018 – 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Share Analysis
8.2. Participant Categorization
8.3. Recent Development and Impact Analysis
Chapter 9. Company Profiles
9.1. Company Overview
9.2. Financial Performance
9.3. Strategic Initiatives
9.3.1. Expansions
9.3.2. Partnerships and Collaborations
9.3.3. Acquisitions
9.3.3.1. Takeda Pharmaceutical Company
9.3.3.2. F. Hoffmann-La Roche Ltd.
9.3.3.3. Pfizer, Inc.
9.3.3.4. AstraZeneca
9.3.3.5. Novartis AG
9.3.3.6. Labcorp Drug Development
9.3.3.7. IQVIA, Inc.
9.3.3.8. Charles River Laboratories
9.3.3.9. Icon Plc
9.3.3.10. Parexel International Corporation
|
| ※본 조사보고서 [세계의 희소 질환 임상 시험 시장 (2023~2030) : 자가 면역 및 염증, 혈액 질환] (코드 : GRV23MR025) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 희소 질환 임상 시험 시장 (2023~2030) : 자가 면역 및 염증, 혈액 질환] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
